Exelixis | EXEL - Current Liabilities


Exelixis reported $405.64M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Akebia Therapeutics USD 133.38M 14.66M Sep/2025
Amgen USD 25.49B 3.7B Dec/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
Bayer EUR 28.96B 825M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Cytokinetics USD 142.14M 11.08M Sep/2025
Eisai JPY 387.67B 9.42B Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Esperion Therapeutics USD 359.03M 60.24M Sep/2025
Exelixis USD 405.64M 31.86M Dec/2025
Genmab DKK 629M 127M Jun/2025
Glaxosmithkline GBP 28.68B 8.3B Sep/2025
Incyte USD 1.52B 176.44M Dec/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
MacroGenics USD 44.47M 5.47M Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Moderna USD 1.99B 306M Dec/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sanofi EUR 28.35B 9.32B Dec/2025
Takeda JPY 2.61T 470.53B Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Xencor USD 86.48M 9.6M Sep/2025